Clinical trials: Inhalation
Covid19
Clinical Trial to Assess the Efficacy and Safety of Inhaled AQ001S in the Management of Acute COVID-19 Symptoms
Double-blind parallel trial to assess the efficacy and safety of inhaled AQ001S in the management of acute COVID-19 symptoms compared.
- Trial name
- SIROCCO-1 (NCT05000346)
- Testing
- Drug, inhalation
- Where
- Belgium
- Volunteers
- 21 people
- Sponsor
- Aquilon Pharmaceuticals S.A.
Asthma
An Open Label Placebo Study to Assess the Inhalation Profile in Asthmatic Patients Using the Nexthaler® Dry Powder Inhaler (DPI) Device
Phase IIa, single-centre, open-label, single-arm study, to evaluate the inspiration profile through the NEXThaler® device in adult asthmatic patients with varying degrees of disease control.
- Trial name
- NEXThalerPIF (NCT01651650)
- Testing
- Inhalation through Chiesi NEXThaler DPI
- Where
- Italy
- Volunteers
- 41 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
Cystic Fibrosis
Inhaled Sodium Pyruvate for the Treatment of Cystic Fibrosis.
It is hypothesized that the inhalation of sodium pyruvate will reduce lung damage in patients with Cystic Fibrosis (CF) by its ability to reduce levels of toxic reactive oxygen and nitrogen compounds associated with the chronic…
- Trial name
- NCT00308243
- Testing
- Sodium Pyruvate in 0.9% Sodium Chloride Solution
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Emphycorp
Pulmonary Disease, Chronic Obstructive
Study Evaluating the Efficacy and Safety of Fluticasone Furoate/Vilanterol Inhalation Powder (FF/VI) Compared With Vilanterol Inhalation Powder (VI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
This is a Phase IIIa, multicenter, randomized, stratified (reversibility status), double-blind, parallel-group study to evaluate the efficacy and safety of FF/VI 100/25 micrograms (mcg) once daily (QD) compared with VI 25 mcg QD…
- Trial name
- NCT02105974
- Testing
- Fluticasone Furoate/Vilanterol, Vilanterol
- Where
- 237 sites in United States, Bulgaria and 9 more
- Volunteers
- 1,621 people
- Sponsor
- GlaxoSmithKline
Asthma, Airway Obstruction
Single-dose Crossover Study to Investigate Pharmacodynamics of AZD3199
The purpose of this study is to investigate the pharmacodynamics of single doses of AZD3199 in asthmatic patients.
- Trial name
- NCT00736489
- Testing
- AZD3199, Formoterol
- Where
- 4 sites in Denmark, Sweden
- Volunteers
- 37 people
- Sponsor
- AstraZeneca
Asthma
Long Term Safety & Efficacy of Budesonide Inhalation Suspension in Japanese Children With Bronchial Asthma
This study is as an extension study of SD-004-0765, to assess the safety profile of long-term use of budesonide inhalation suspension in Japanese young children with bronchial asthma.
- Trial name
- NCT00232648
- Testing
- Pulmicort (budesonide) Respules
- Where
- 9 sites in Japan
- Volunteers
- 54 people
- Sponsor
- AstraZeneca
Sleep Disordered Breathing, Obstructive Sleep Apnea
The Evaluation of a Nasal Mask for the Treatment of Obstructive Sleep Apnea
This investigation is designed to evaluate the performance as well as the patients overall acceptance of the mask.
- Trial name
- NCT03156413
- Testing
- F&P nasal mask
- Where
- New Zealand
- Volunteers
- 12 people
- Sponsor
- Fisher and Paykel Healthcare
Waste Anesthetic Gas (WAG) Emanating From Patients Post-operative Recovery
Evaluation and Control of WAG in PACU Within Patient and Caregiver Breathing Zone
The purpose of this study is to evaluate anesthetic gas in the PACU within patient and caregiver breathing zones.
- Trial name
- NCT02428413
- Testing
- ISO-Gard Mask, Standard oxygen mask
- Volunteers
- 125 people
- Sponsor
- Teleflex
Cystic Fibrosis
Safety and Efficacy Study of Aztreonam for Inhalation Solution (AZLI) in Cystic Fibrosis Patients With P. Aeruginosa
The purpose of this study was to evaluate the safety and efficacy of aztreonam for inhalation solution (AZLI) in patients with cystic fibrosis (CF) and lung infection due to Pseudomonas aeruginosa (PA).
- Trial name
- AIR-CF2 (NCT00104520)
- Testing
- AZLI 75 mg two times a day (BID)/three times a day (TID)
- Where
- 56 sites in United States
- Volunteers
- 211 people
- Sponsor
- Gilead Sciences
Chronic Obstructive Pulmonary Disease (COPD)
A Trial to Evaluate the Safety and Efficacy of HL231 Solution for Inhalation in Patients with COPD
To evaluate the efficacy and safety of HL231 Solution for Inhalation vs Ultibro in Chinese patients with moderate to severe COPD.
- Trial name
- NCT06619210
- Testing
- HL231 Dose 1/2/3/4
- Where
- China
- Volunteers
- 102 people
- Sponsor
- Haisco Pharmaceutical Group Co., Ltd.
Heart Failure (HF)
SchlaHF-XT-Register. Sleep Disordered Breathing in Heart Failure Register
The SchlaHF XT Registry is a longitudinal study of patients with heart failure (HF). The study aims to understand the importance of diagnosis and treatment of sleep disordered breathing (SDB) on HF with the following questions…
- Trial name
- NCT02301689
- Where
- Germany
- Volunteers
- 4,749 people
- Sponsor
- ResMed
Lung Transplant Rejection
An Open Label Trial Evaluating the Safety, Tolerability, Efficacy and Pharmacokinetic Profile of Tacrolimus Inhalation Powder in Adult Lung Transplant Recipients
Part A: This is an open label, single-arm study that will evaluate the safety, tolerability, efficacy and PK of Tacrolimus Inhalation Powder over 12 weeks in lung transplant patients who require reduced blood levels of tacrolimus…
- Trial name
- NCT05501574
- Testing
- Tacrolimus Inhalation Powder, Plastiape RS00 Dry Powder inhaler device
- Where
- 2 sites in Australia
- Volunteers
- 14 people
- Sponsor
- TFF Pharmaceuticals, Inc.
Pulmonary Disease, Chronic Obstructive
A Long-term Safety Study of Fluticasone Furoate (FF)/GW642444 in Japanese Subjects With COPD
The primary purpose of the study is to evaluate the safety and tolerability of fluticasone furoate/GW642444 inhalation powder when administered once-daily for 52 weeks in Japanese patients with COPD.
- Trial name
- NCT01192191
- Testing
- Fluticasone Furoate/GW642444 Inhalation Powder 100/25mcg, Fluticasone Furoate/GW642444 Inhalation Powder 200/25mcg
- Where
- 35 sites in Japan
- Volunteers
- 187 people
- Sponsor
- GlaxoSmithKline
Pulmonary Hypertension, Interstitial Lung Disease
An Open-Label Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
The primary objective of this study is to evaluate the safety and tolerability of the long-term use of TPIP in participants with PH-ILD from Study INS1009-311 (NCT07179380).
- Trial name
- NCT07234032
- Testing
- Treprostinil Palmitil Inhalation Powder
- Where
- 11 sites in United States, Czechia and 6 more
- Volunteers
- 344 people
- Sponsor
- Insmed Incorporated
Chronic Obstructive Pulmonary Disease (COPD)
Effects of Mometasone Furoate/Formoterol Combination Versus Formoterol and Mometasone Furoate Alone in Chronic Obstructive Pulmonary Disease (COPD) (Study P04230AM4)(COMPLETED)
This is a randomized, placebo-controlled, parallel-group, multi-site, double-blind study evaluating the efficacy of mometasone furoate/formoterol fumarate (MF/F) metered dose inhaler (MDI) 400/10 mcg twice daily (BID) and MF/F…
- Trial name
- NCT00383721
- Testing
- Mometasone furoate/formoterol (MF/F) combination, Mometasone furoate MDI (MF MDI), Formoterol MDI
- Volunteers
- 1,196 people
- Sponsor
- Organon and Co
Asthma
Proof of Concept Study of Rilzabrutinib in Adult Participants With Moderate-to-severe Asthma
This is a parallel, treatment, Phase 2, double-blind, 2 arm, 12-week Proof of Concept (PoC) study with 2 staggered cohorts (2 arms in each cohort) that is designed to assess the efficacy, safety, and tolerability of rilzabrutinib…
- Trial name
- NCT05104892
- Testing
- Rilzabrutinib
- Where
- 51 sites in Argentina, Bulgaria and 11 more
- Volunteers
- 196 people
- Sponsor
- Sanofi
Chronic Obstructive Pulmonary Disease
A Study in Patients With Chronic Obstructive Pulmonary Disease (FAIR)
The purpose of the present study is to demonstrate the higher efficacy of small particles Foster® 100/6 (two puffs b.i.d.) versus large particles Symbicort® 200/6 (two inhalations b.i.d.), in terms of residual volume reduction…
- Trial name
- FAIR (NCT01351792)
- Testing
- Foster® 100/6 µg/unit dose, Symbicort® Turbohaler® 200/6 μg/actuation
- Where
- Netherlands
- Volunteers
- 113 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
Sleep Disordered Breathing
Evaluation of Software Enhancements to the Respironics BiPAP autoSV Device Compared to BiPAP S/T Device
This study is being undertaken to collect data from Respironics, Inc's BiPAP autoSV3 and compare with data from Respironics, Inc's BiPAP S/T device, to confirm that the algorithms in the BiPAP autoSV3 device can safely and…
- Trial name
- SV3-ST (NCT01241604)
- Testing
- BiPAP S/T, BiPAP Auto SV3
- Where
- United States
- Volunteers
- 11 people, healthy volunteers welcome
- Sponsor
- Philips Respironics
Safety Issues
Phase 1A Safety Trial of Inhaled PK10571 (GB002)
This is a phase 1A randomized double blind placebo controlled single ascending dose and multiple ascending dose trial of inhaled PK10571 (GB002) in healthy adult subjects.
- Trial name
- NCT03473236
- Testing
- GB002, Generic Dry Powder Inhaler
- Where
- United States
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- GB002, Inc., a wholly owned subsidiary of Gossamer Bio, Inc.
Haemorrhage
A Non-investigational Product (IP) Study to Investigate Lung Function in Women in the Third Stage of Labour
The purpose of this study is to record and compare the inhalation profiles of non pregnant women and those who are in the third stage of labour.
- Trial name
- NCT02106000
- Testing
- Inhalation profile recorder
- Where
- 2 sites in United Kingdom
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.